文献速递临床试验与 GCP真实世界研究与卫生经济

评估药房戒烟治疗优化(STOP)干预的有效性和成本效果:整群随机对照试验方案

Evaluating the effectiveness and cost-effectiveness of the Smoking Treatment Optimisation in Pharmacies (STOP) intervention: protocol for a cluster randomised controlled trial.
PubMed 文献 · Trials · 2019-06-10

该整群随机对照试验在英格兰和威尔士的60家社区药房开展,比较药房戒烟治疗优化(STOP)干预与常规护理对吸烟者参与、留存和戒烟的影响。主要结局为吞吐量,即加入项目、设定明确戒烟日并接受至少一次戒烟治疗课程的吸烟者人数,采用常规收集数据测量;次要结局包括4周留存率和戒烟率及6个月经唾液可替宁验证的持续戒断,并评估成本效果。

要点

  • STOP干预基于行为和组织理论,包括员工教育课程和药房环境提示。
  • 主要结局为吞吐量,即加入项目、设定明确戒烟日并接受至少一次戒烟治疗课程的吸烟者人数。
  • 次要结局包括4周留存率和戒烟率及6个月经唾液可替宁验证的持续戒断。

核心结论

  • 该试验将生成证据以指导英格兰和威尔士的公共卫生戒烟策略,并可能有助于 shaping 服务委托决策。
  • STOP干预模型可能有助于为社区药房中一系列健康行为改变任务的开展提供信息。

研究设计与样本

  • 务实性整群随机对照试验,在英格兰和威尔士的60家药房开展。
  • 干预药房的所有工作人员接受STOP培训,对照药房提供常规护理。
  • 通过演员假扮吸烟者访问药房评估干预保真度。

主要发现

  • 主要结局为吞吐量,定义为加入项目、设定明确戒烟日并接受至少一次戒烟治疗课程的吸烟者人数,采用常规收集数据测量。
  • 次要结局包括4周留存率和戒烟率及6个月经唾液可替宁验证的持续戒断。
  • 成本效果使用质量调整生命年估计,并计算在不同支付意愿水平下干预有效的概率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: NHS community pharmacies provide effective smoking cessation services; however, there is scope for increasing throughput and improving quit rates. This trial examines whether the Smoking Treatment Optimisation in Pharmacies (STOP) intervention can improve smoker engagement to increase service throughput, retention and quitting. METHODS: This study is a pragmatic, cluster randomised controlled trial in 60 pharmacies in England and Wales. All workers in intervention pharmacies are offered STOP training while control pharmacies provide usual care. The STOP intervention, based on behavioural and organisational theories, comprises educational sessions for staff and environmental prompts in the pharmacy. Intervention fidelity is assessed by actors visiting pharmacies posing as smokers. The primary outcome is throughput, defined as the number of smokers who join the programme, set a firm quit date and undergo at least one stop smoking treatment session, and is measured using routinely collected data. Secondary outcomes include retention and quit rates at 4 weeks and continuous abstinence at 6 months verified by salivary cotinine. Cost-effectiveness is estimated using quality-adjusted life years and the probability that the intervention is effective at different levels of willingness to pay is calculated. DISCUSSION: The trial will generate evidence to inform the public health smoking cessation strategy in England and Wales, and may help to shape service commissioning decisions. The STOP intervention model may help inform the undertaking of a range of health behaviour change tasks in community pharmacies. TRIAL REGISTRATION: ClinicalTrials.gov, ISRCTN16351033. Retrospectively registered on 21 March 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sohanpal R, Jumbe S, James WY, et al. Evaluating the effectiveness and cost-effectiveness of the Smoking Treatment Optimisation in Pharmacies (STOP) intervention: protocol for a cluster randomised controlled trial. Trials. 2019. PMID: 31182134. doi:10.1186/s13063-019-3368-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。